Search
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Estradiol benzoate
go.drugbank.com/drugs/DB13953ApprovedVet approvedWithdrawnFirst-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. … Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. Estradiol benzoate is not currently available in Canada or the US.
Categories: EstranesSARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market. … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer.
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.
Tetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalThe only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … Tetraethylammonium is an experimental drug with no approved indication or marketed formulation.
Somatrem
go.drugbank.com/drugs/DB09098ApprovedWithdrawncontinues to be mired in persistent bioethical debate [A32292]. … Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedDasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label].
Categories: Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase InhibitorSynonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamidePegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.